Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
- Status
- UNKNOWN
- Phase
- N/A
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Status
- WITHDRAWN
- Phase
- PHASE3
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- Status
- TERMINATED
- Phase
- PHASE2
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2